Antonio Maggi Joins Nemysis Ltd Board of Directors

DUBLIN, June 10, 2020 (Newswire.com) - ​​Antonio Maggi, Senior Executive, specializing in marketing and sales network management, has over 30 years of experience in various industries. Over the last 25 years, his experience has focused on the pharmaceutical sector with expertise in the development of start-up companies for which he has defined their long-term strategies and planned all pre- and post-marketing activities.

Antonio has also held academic positions for over ten years as a university professor dealing with market policies related to health and the drug market.

"Antonio will add significant value as a Nemysis board member, drawing on his experience and professional network, particularly as we are preparing our first commercial presence in the European market. We look forward to benefiting from his expertise as we continue to grow the company," said Marco Cartolari, Co-Founder and Director.

Antonio stated: "Joining the Board of Directors is a privilege for me. I enthusiastically welcomed the proposal to join Nemysis, a company that from the very first moment impressed me for its dynamism, for the innovation of its projects and for the spirit that animates its members. Contributing to the achievement of the ambitious goals of the company makes me proud, and it will be exciting to work towards future success with all my colleagues."

Antonio has a Master Degree in Economics from Politecnico delle Marche University.

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focussed on nutritional and pharmaceutical solutions which can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

•  Nemysis's novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials. ​
• Nemysis's novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity. ​​

Nemysis has three further products in its pipeline for use in Iron Deficiency/Anaemia, Gluten sensitivity and Celiac Disease.

Read more www.nemysisltd.com

Danilo Casadei -Massari​
Chairman of the Board
​Nemysis Ltd
7 D'Olier Street
D02HF60 Dublin
Ireland
+35315313450
[email protected] 

Source: NEMYSIS LTD